Remternetug

DRUG4 trials

Sponsors

Eli Lilly & Co., Washington University School Of Medicine, Washington University School of Medicine, Eli Lilly and Company

Conditions

Alzheimer's DiseaseAlzheimers DiseaseAlzheimers Disease, FamilialAlzheimer’s DiseaseDementiaDominantly Inherited Alzheimer’s Disease (DIAD)

Phase 2

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

RecruitingNCT06647498

Washington University School of MedicineAlzheimers Disease, Alzheimers Disease, Familial, Dementia

Start: 2024-11-22End: 2034-08-01Target: 280Updated: 2026-02-13

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-Stage Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer’s Disease

Not yet recruitingCTIS2024-517187-36-01

Washington University School Of MedicineDominantly Inherited Alzheimer’s Disease (DIAD)

Target: 27Updated: 2025-10-20

Phase 3

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

Active, not recruitingNCT06653153

Eli Lilly and CompanyAlzheimer's Disease

Start: 2024-10-24End: 2030-10-31Target: 1400Updated: 2025-11-20

J1G-MC-LAKI: A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease Participants at Risk for Cognitive and Functional Decline

Active, not recruitingCTIS2024-515656-20-00

Eli Lilly & Co.Alzheimer’s Disease

Start: 2025-04-15Target: 43Updated: 2025-11-24